Randall R De Martino1, Jens Eldrup-Jorgensen2, Brian W Nolan3, David H Stone3, Julie Adams4, Daniel J Bertges4, Jack L Cronenwett3, Philip P Goodney3. 1. Section of Vascular Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Division of Vascular and Endovascular Surgery, Mayo Clinic, Rochester, Minn. Electronic address: demartino.randall@mayo.edu. 2. Maine Medical Center, Portland, Me. 3. Section of Vascular Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH. 4. Division of Vascular Surgery, University of Vermont College of Medicine, Burlington, Vt.
Abstract
OBJECTIVE: Many patients undergoing vascular surgical procedures are not on appropriate medical therapy. This study sought to examine the variation and impact of antiplatelet (AP) and statin therapy on early and late mortality in patients undergoing vascular surgery in our region. METHODS: We studied all patients (n = 14,489) undergoing elective carotid endarterectomy (n = 6978), carotid stenting (n = 524), and suprainguinal (n = 763) and infrainguinal bypass (n = 3053), as well as patients with known coronary risk factors undergoing open (n = 1044) and endovascular (n = 2127) abdominal aortic aneurysm repair from 2005 to 2012 in the Vascular Study Group of New England. Optimal medical management was defined as treatment with both AP and statin agents, preoperatively and at discharge. We analyzed temporal, procedural, and center variation of medication use. Multivariable analyses were used to determine the adjusted impact of AP and statin therapy on 30-day mortality and 5-year survival. RESULTS: Optimal medical management improved over the study interval (55% in 2005 to 68% in 2012; P trend < .01) with carotid interventions having the highest rates of optimal medications use (carotid artery stenting, 78%; carotid endarterectomy, 74%) and abdominal aortic aneurysm repair in patients with known cardiac risk factors having the lowest (open, 57%; endovascular aneurysm repair, 56%). Optimal medication use varied by center as well (range, 40%-86%). Preoperative AP and statin use was associated with reduced 30-day mortality (odds ratio, 0.76; 95% confidence interval [CI], 0.5-1.05; P = .09). AP and statin prescription at discharge was additive in survival benefit with improved 5-year survival (hazard ratio, 0.5; 95% CI, 0.4-0.7; P < .01) that was consistent across procedure types. Patients prescribed AP and statin at discharge had 5-year survival of 79% (95% CI, 77%-81%) compared with only 61% (95% CI, 52%-68%; P < .001) for patients on neither medication. CONCLUSIONS: AP and statin therapy preoperatively and at discharge was associated with reduced 30-day mortality and an absolute 18% improved 5-year survival after vascular surgery. However, one-third of patients are suboptimally managed in real world practice. This demonstrates an opportunity for quality improvement that can substantially improve survival after vascular surgery.
OBJECTIVE: Many patients undergoing vascular surgical procedures are not on appropriate medical therapy. This study sought to examine the variation and impact of antiplatelet (AP) and statin therapy on early and late mortality in patients undergoing vascular surgery in our region. METHODS: We studied all patients (n = 14,489) undergoing elective carotid endarterectomy (n = 6978), carotid stenting (n = 524), and suprainguinal (n = 763) and infrainguinal bypass (n = 3053), as well as patients with known coronary risk factors undergoing open (n = 1044) and endovascular (n = 2127) abdominal aortic aneurysm repair from 2005 to 2012 in the Vascular Study Group of New England. Optimal medical management was defined as treatment with both AP and statin agents, preoperatively and at discharge. We analyzed temporal, procedural, and center variation of medication use. Multivariable analyses were used to determine the adjusted impact of AP and statin therapy on 30-day mortality and 5-year survival. RESULTS: Optimal medical management improved over the study interval (55% in 2005 to 68% in 2012; P trend < .01) with carotid interventions having the highest rates of optimal medications use (carotid artery stenting, 78%; carotid endarterectomy, 74%) and abdominal aortic aneurysm repair in patients with known cardiac risk factors having the lowest (open, 57%; endovascular aneurysm repair, 56%). Optimal medication use varied by center as well (range, 40%-86%). Preoperative AP and statin use was associated with reduced 30-day mortality (odds ratio, 0.76; 95% confidence interval [CI], 0.5-1.05; P = .09). AP and statin prescription at discharge was additive in survival benefit with improved 5-year survival (hazard ratio, 0.5; 95% CI, 0.4-0.7; P < .01) that was consistent across procedure types. Patients prescribed AP and statin at discharge had 5-year survival of 79% (95% CI, 77%-81%) compared with only 61% (95% CI, 52%-68%; P < .001) for patients on neither medication. CONCLUSIONS: AP and statin therapy preoperatively and at discharge was associated with reduced 30-day mortality and an absolute 18% improved 5-year survival after vascular surgery. However, one-third of patients are suboptimally managed in real world practice. This demonstrates an opportunity for quality improvement that can substantially improve survival after vascular surgery.
Authors: Thomas G Brott; Robert W Hobson; George Howard; Gary S Roubin; Wayne M Clark; William Brooks; Ariane Mackey; Michael D Hill; Pierre P Leimgruber; Alice J Sheffet; Virginia J Howard; Wesley S Moore; Jenifer H Voeks; L Nelson Hopkins; Donald E Cutlip; David J Cohen; Jeffrey J Popma; Robert D Ferguson; Stanley N Cohen; Joseph L Blackshear; Frank L Silver; J P Mohr; Brajesh K Lal; James F Meschia Journal: N Engl J Med Date: 2010-05-26 Impact factor: 91.245
Authors: D J Adam; J D Beard; T Cleveland; J Bell; A W Bradbury; J F Forbes; F G R Fowkes; I Gillepsie; C V Ruckley; G Raab; H Storkey Journal: Lancet Date: 2005-12-03 Impact factor: 79.321
Authors: A T Hirsch; M H Criqui; D Treat-Jacobson; J G Regensteiner; M A Creager; J W Olin; S H Krook; D B Hunninghake; A J Comerota; M E Walsh; M M McDermott; W R Hiatt Journal: JAMA Date: 2001-09-19 Impact factor: 56.272
Authors: Jack L Cronenwett; Donald S Likosky; Margaret T Russell; Jens Eldrup-Jorgensen; Andrew C Stanley; Brian W Nolan Journal: J Vasc Surg Date: 2007-10-24 Impact factor: 4.268
Authors: N R Hertzer; E G Beven; J R Young; P J O'Hara; W F Ruschhaupt; R A Graor; V G Dewolfe; L C Maljovec Journal: Ann Surg Date: 1984-02 Impact factor: 12.969
Authors: Alan T Hirsch; Ziv J Haskal; Norman R Hertzer; Curtis W Bakal; Mark A Creager; Jonathan L Halperin; Loren F Hiratzka; William R C Murphy; Jeffrey W Olin; Jules B Puschett; Kenneth A Rosenfield; David Sacks; James C Stanley; Lloyd M Taylor; Christopher J White; John White; Rodney A White; Elliott M Antman; Sidney C Smith; Cynthia D Adams; Jeffrey L Anderson; David P Faxon; Valentin Fuster; Raymond J Gibbons; Sharon A Hunt; Alice K Jacobs; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel Journal: Circulation Date: 2006-03-21 Impact factor: 29.690
Authors: Frank A Lederle; Julie A Freischlag; Tassos C Kyriakides; Frank T Padberg; Jon S Matsumura; Ted R Kohler; Peter H Lin; Jessie M Jean-Claude; Dolores F Cikrit; Kathleen M Swanson; Peter N Peduzzi Journal: JAMA Date: 2009-10-14 Impact factor: 56.272
Authors: Paul E Norman; Konrad Jamrozik; Michael M Lawrence-Brown; Max T Q Le; Carole A Spencer; Raywin J Tuohy; Richard W Parsons; James A Dickinson Journal: BMJ Date: 2004-11-15
Authors: Ali F AbuRahma; Mohit Srivastava; Patrick A Stone; Bryan K Richmond; Zachary AbuRahma; Will Jackson; L Scott Dean; Albeir Y Mousa Journal: J Am Coll Surg Date: 2014-12-15 Impact factor: 6.113
Authors: Peter A Soden; Sara L Zettervall; Sarah E Deery; Kakra Hughes; Michael C Stoner; Philip P Goodney; Ageliki G Vouyouka; Marc L Schermerhorn Journal: J Vasc Surg Date: 2017-09-23 Impact factor: 4.268
Authors: Randall R DeMartino; Ying Huang; Jay Mandrekar; Philip P Goodney; Gustavo S Oderich; Manju Kalra; Thomas C Bower; Jack L Cronenwett; Peter Gloviczki Journal: J Vasc Surg Date: 2017-08-12 Impact factor: 4.268
Authors: Benjamin S. Brooke; Adam W. Beck; Larry W. Kraiss; Andrew W. Hoel; Andrea M. Austin; Amir A. Ghaffarian; Jack L. Cronenwett; Philip P. Goodney Journal: JAMA Surg Date: 2018-03-01 Impact factor: 14.766
Authors: Peter A Soden; Sara L Zettervall; Klaas H J Ultee; Bruce E Landon; A James O'Malley; Philip P Goodney; Randall R DeMartino; Shipra Arya; Marc L Schermerhorn Journal: J Vasc Surg Date: 2016-08-27 Impact factor: 4.268
Authors: Peter A Soden; Sara L Zettervall; Thomas Curran; Ageliki G Vouyouka; Philip P Goodney; Joseph L Mills; John W Hallett; Marc L Schermerhorn Journal: J Vasc Surg Date: 2016-09-28 Impact factor: 4.268
Authors: Randall R De Martino; Adam W Beck; Andrew W Hoel; John W Hallett; Shipra Arya; Gilbert R Upchurch; Jack L Cronenwett; Philip P Goodney Journal: J Vasc Surg Date: 2015-09-26 Impact factor: 4.268